This is an indefinite delivery/indefinite quantity (IDIQ) contract for conducting postmarket bioequivalence studies of generic drug products. The contract has a five-year ordering period, with a guaranteed minimum of $2,**** for the first task order, and an estimated maximum contract amount not to exceed $20,000,**** are due August 21, 2025, at 10:00 AM Eastern Time. Clarification questions are due August 13, 2025, at 10:00 AM Eastern Time. The proposal must include three volumes: technical proposal (maximum 35 pages), business/price proposal, and past performance proposal. The evaluation will be based on a best value approach, considering technical factors (technical understanding, staffing, equipment) and past performance, with price being a factor only when technical ratings are close.
Proposals are due by 10:00 AM Eastern on August 21, 2025.
Payment will be made no more frequently than monthly, in arrears, for services/supplies rendered to and accepted by the government, in accordance with the applicable invoice clause with the task order contract type specified (i. e. , fixed price, time-and-material, and/or labor hour basis).
The government intends to award a single-award IDIQ contract to the responsible offeror whose proposal, conforming to the solicitation, represents the best value to the government, considering technical, price, and other factors.
The offeror shall provide a narrative description of the qualifications of proposed key personnel demonstrating that they meet the stated minimum experience and qualifications to satisfy requirements.
The maximum contract amount, inclusive of the five-year ordering period under the contract is estimated not to exceed $20,000,****.
